Trial Profile
Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Mar 2024 Planned End Date changed from 31 Aug 2024 to 31 Mar 2026.
- 07 Mar 2024 Planned primary completion date changed from 12 Jul 2024 to 31 Mar 2025.
- 06 Jun 2023 Results of 26 additional patients after safety run in, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.